Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-08-10 02:02 UTC

BIOMED PULSE

August 10, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo Ebola outbreak in DRC and Uganda has now surpassed 2,100 confirmed cases and 828 deaths as of July 15, making it the largest Bundibugyo virus event on record — and it is still intensifying. [1] The overall mood is urgent on the viral front, cautiously optimistic on longevity science, with a notable metformin-for-aging trial delivering sobering results.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO EBOLA — DRC AND UGANDA (ACTIVE, INTENSIFYING)

  • As of July 15, 2026, WHO confirms 2,124 confirmed cases and 828 deaths (case fatality ~39%) across DRC and Uganda, with sustained cross-border transmission. [1]
  • The outbreak originated in Mongbwalu Health Zone, Ituri Province, DRC, first flagged May 5, 2026, confirmed as Bundibugyo virus (not Ebola Zaire) by the Institut national de recherche biomédicale (INRB) on May 14. [2]
  • Geographic spread has expanded well beyond Ituri over the past two months, with Uganda reporting ongoing cross-border cases. [3]
  • CDC mobilized an international Ebola response beginning May 17, 2026, and expanded enhanced airport screening from Washington-Dulles to Atlanta Hartsfield-Jackson. [4] [5] [6]
  • WHO's August 1 DON (disease outbreak news, DON614) describes the outbreak as "intensifying" with no indication of containment. [3]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • WHO's fifth DON (DON611, July 2, 2026) on the Andes hantavirus (ANDV) outbreak traces the cluster to the cruise ship M/V Hondius, first notified to WHO on May 2, 2026. [7]
  • CDC has been providing regular response transcripts through at least June 24, 2026, confirming ongoing monitoring of cases among passengers and crew from multiple countries. [8]
  • Andes hantavirus causes hantavirus pulmonary syndrome, a severe respiratory illness with significant mortality; person-to-person transmission of ANDV is documented, unlike other hantavirus strains. [9] [7]

CYCLOSPORA — TACO BELL / SHREDDED ICEBERG LETTUCE, FIVE STATES

  • CDC confirmed on July 17, 2026, that shredded iceberg lettuce served at Taco Bell locations is the source of Cyclospora cayetanensis infections across five states, with 1,644 people sick. [10]
  • As of July 24, 2026, the Cyclospora outbreak linked to iceberg lettuce expanded to four additional states.
  • Cyclospora is a parasitic pathogen causing prolonged watery diarrhea; past U.S. outbreaks have been tied to imported produce. [10]

SALMONELLA — JALAPEÑOS, MULTISTATE

  • CDC posted a new food safety alert on August 5, 2026, warning of a multistate Salmonella outbreak linked to jalapeños.

NIPAH VIRUS — KERALA, INDIA

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed Nipah virus (NiV) infection in an adult male in Kozhikode district; the patient developed neurological symptoms on May 30, 2026, and was hospitalized June 10.
  • WHO assessed the risk of further international spread as low but noted Kerala has experienced prior NiV outbreaks, and contact tracing was underway.

YELLOW FEVER — GLOBAL

  • WHO's June 24, 2026, DON reports that from January 1 to May 26, 2026, six countries reported 79 human infections; sustained transmission activity carried over from an elevated 2025 Americas season.

MEASLES — BANGLADESH AND GLOBAL CONTEXT

  • WHO reported April 23, 2026, that Bangladesh logged 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts, all eight divisions affected.
  • Global context: CDC data from late 2024 recorded 10.3 million measles infections worldwide in 2023, underscoring declining vaccination coverage.

MPOX — RECOMBINANT CLADE Ib/IIb STRAIN

  • WHO reported in February 2026 (DON595) two cases of a recombinant mpox strain combining genomic elements of clade Ib and clade IIb monkeypox virus (MPXV), documenting natural recombination when two strains co-infect a single individual.

DRUG-RESISTANT BACTERIA — U.S. DOMESTIC

  • A CDC report published September 23, 2025, found a dramatic rise in dangerous drug-resistant bacteria in the United States, continuing the trend flagged in prior antimicrobial resistance threat reports.
  • Extensively drug-resistant (XDR) Salmonella has also been documented in the ongoing moringa leaf powder supplement outbreak, with three hospitalizations reported as of February 2026.

🧬 LONGEVITY & AGING

METFORMIN FOR PHYSICAL FUNCTION IN OLDER ADULTS — SOBERING TRIAL RESULTS

  • The DEMFOS randomized controlled trial (Lancet Healthy Longevity, published ahead of print) tested metformin added to lifestyle intervention in older adults with obesity, measuring physical function outcomes; results indicate the drug's incremental benefit over lifestyle alone is modest, prompting an accompanying editorial to caution against "inflated expectations" for metformin as a broad anti-aging agent.
  • Principal investigators include Nava MLD, Viola V, Aguilar M, Villareal DT, and colleagues; the editorial is authored by Witham MD and McDonald C.

PUNICALAGIN AND BONE STEM CELL SENESCENCE

  • A Europe PMC study (Regen Ther, July 25, 2026) by Wang Y and colleagues shows that punicalagin — a polyphenol from pomegranate — alleviates senile osteoporosis in a model system by inhibiting senescence of bone mesenchymal stem cells (BMSCs) via activation of the NRF2/HO-1 antioxidant pathway.
  • BMSC senescence is a key mechanism driving age-related bone loss; the NRF2 pathway is an established cellular stress-response and longevity-associated target.

COLLAGEN XVII AND EPIDERMAL STEM CELL PHOTOAGING

  • Wang X and colleagues (Ann Med, July 16, 2026) report that recombinant human collagen XVII protects epidermal stem cells from blue-light-induced photoaging by downregulating the Notch signaling pathway.
  • Collagen XVII anchors epidermal stem cells to the basement membrane; its decline with age is associated with hair follicle and skin aging.

SENESCENCE MARKER P16INK4A — DETECTION VALIDATION

  • Pipella J and Thompson PJ (Islets, July 21, 2026) publish methodological work stressing the critical importance of antibody validation when detecting the cellular senescence marker p16INK4A by immunohistochemistry in pancreatic tissue.
  • Accurate p16INK4A detection is fundamental to senescent cell research, including senolytics trials targeting pancreatic beta-cell aging.

TELOMERE REPAIR AND NUCLEAR ARCHITECTURE IN CANCER CELLS

  • Salmina K and colleagues (Nucleus, July 23, 2026) examine repair and misrepair of telomeric DNA in doxorubicin-treated cancer cells, finding dynamic interactions with PML nuclear bodies and lamin B1 — structures whose dysfunction is also implicated in normal aging (progeria, nuclear lamina decline).

LYSOSOMAL AMPK ACTIVATION FOR FATTY LIVER DISEASE

  • Zhu J and colleagues (Bioact Mater, July 12, 2026) report that targeting ROAM1 with UDP-GlcNAc nanosheets selectively activates lysosomal AMPK to resolve metabolic dysfunction-associated steatotic liver disease (MASLD) in a preclinical model.
  • AMPK activation via the lysosomal pathway is a mechanism shared with metformin and rapamycin, both studied in aging biology.

POSITIVE LIFE ORIENTATION AND BLOOD PRESSURE IN OLDER ADULTS

  • Lääti A and colleagues (Blood Press, Aug 7, 2026) using two Finnish generational cohorts born 20 years apart find that positive life orientation is associated with lower blood pressure in older adults, with the association holding across generations.

CANINE EPIGENETIC AGING AND DIET — PILOT STUDY

  • Chen A, Guo W, and colleagues (Vet Rec Open, Aug 5, 2026) report in a pilot study that switching dogs to a minimally processed, human-grade diet alters canine epigenetic aging clocks, potentially slowing biological age accrual — a finding relevant to mammalian dietary aging research.

DEPRESCRIBING IN OLDER ADULTS — FRAMEWORK DEBATE

  • Two Lancet Healthy Longevity correspondences (July 8, 2026) argue that deprescribing trials in older patients require a rationale-first framework before choosing trial design, highlighting methodological gaps in polypharmacy-reduction research relevant to healthy aging.

💊 NEW CURES & APPROVALS

FOUNDAYO (ORFORGLIPRON CALCIUM) — ELI LILLY AND CO

  • openFDA records a supplemental approval (SUPPL AP) for Foundayo, containing orforglipron calcium, from Eli Lilly and Co (NDA220934); orforglipron is an oral non-peptide GLP-1 receptor agonist being developed for type 2 diabetes and obesity, representing a pill-form alternative to injectable GLP-1 drugs.

ORZEYFUL (OVEPOREXTON) — TAKEDA PHARMACEUTICALS USA

  • openFDA records an original approval (ORIG AP) for Orzeyful, containing oveporexton, from Takeda Pharmaceuticals USA (NDA220860); oveporexton is an orexin 2 receptor agonist indicated for narcolepsy type 1, a disorder involving loss of orexin-producing neurons.

NINTEDANIB ESYLATE GENERIC — MACLEODS PHARMACEUTICALS LTD

  • openFDA records an original generic approval (ORIG AP) for nintedanib esylate from Macleods Pharmaceuticals Ltd (ANDA219926); nintedanib is a tyrosine kinase inhibitor used for idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated ILD, expanding access to a reference-listed drug.

SACUBITRIL AND VALSARTAN GENERIC — UMEDICA

  • openFDA records an original generic approval (ORIG AP) for the sacubitril/valsartan combination from Umedica (ANDA219946); the brand Entresto (Novartis) is a neprilysin inhibitor/angiotensin receptor blocker combination approved for heart failure with reduced ejection fraction.

TERIPARATIDE (FORTEO) SUPPLEMENT — LILLY; ALMAJECT

  • openFDA records supplemental approvals for teriparatide (synthetic parathyroid hormone fragment) under both Forteo/Lilly (NDA021318) and a second NDA under Almaject (NDA218771); teriparatide is used for osteoporosis in high-fracture-risk patients.

ABALOPARATIDE (TYMLOS) SUPPLEMENT — RADIUS

  • openFDA records a supplemental approval for abaloparatide (Tymlos) from Radius Health (NDA208743); abaloparatide is a PTHrP analogue for postmenopausal osteoporosis with high fracture risk.

🧪 CLINICAL TRIALS

B7-H3 CAR-T FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER — NIH/NCI

  • NCT07509034 (posted Aug 7, 2026): an autologous B7-H3 chimeric antigen receptor T-cell therapy trial for previously treated extensive-stage small cell lung cancer (SCLC) and extrapulmonary neuroendocrine cancer (EPNEC); B7-H3 is a checkpoint-like protein overexpressed on SCLC tumor cells.

NEOANTIGEN-TARGETED TCR T-CELLS FOR TP53/RAS-MUTATED BLOOD CANCERS — NIH

  • NCT06904066 (posted Aug 7, 2026): autologous T cells transduced with retroviral vectors expressing patient-specific neoantigen-targeted TCRs for hematologic malignancies including leukemias harboring TP53 or RAS mutations.

BASE EDITING FOR X-LINKED CHRONIC GRANULOMATOUS DISEASE — NIH

  • NCT06325709 (posted Aug 7, 2026): a trial testing base-editing gene therapy in hematopoietic stem and progenitor cells to repair CYBB gene mutations causing X-linked chronic granulomatous disease, an immune disorder with high infection susceptibility.

INTRANASAL/INHALED SARS-COV-2 VACCINE OCU500 — PHASE 1

  • NCT07536308 (posted Aug 7, 2026): a Phase 1 randomized open-label dose-escalation trial of OCU500, a ChAd36 adenoviral vector encoding SARS-CoV-2 spike protein, delivered intranasally and by inhalation, in adults aged 18-64 who completed primary COVID-19 vaccination plus at least one booster.

RIMEGEPANT VS FLUNARIZINE FOR VESTIBULAR MIGRAINE — NON-INFERIORITY RCT

  • NCT07751497 (posted Aug 7, 2026): a randomized, open-label, multi-center non-inferiority trial comparing rimegepant (a CGRP receptor antagonist) to flunarizine for prevention of vestibular migraine, affecting 1-2.7% of the general population.

MIRDAMETINIB PLUS SIROLIMUS FOR RAS-MUTATED MULTIPLE MYELOMA — NIH

  • NCT06876142 (posted Aug 7, 2026): a combination therapy trial of mirdametinib (MEK inhibitor) and sirolimus (mTOR inhibitor) for KRAS/NRAS-mutated relapsed/refractory multiple myeloma.

VENETOCLAX DURATION COMPARISON IN OLDER AML PATIENTS — MYLELOMATCH

  • NCT07437950 (posted Aug 7, 2026): a Phase II MyeloMATCH trial comparing standard versus shorter duration venetoclax combined with ASTX727 (decitabine/cedazuridine) for newly diagnosed acute myeloid leukemia (AML) in older patients; decitabine is a hypomethylating agent.

PfSPZ-LARC2 MALARIA VACCINE — PHASE 1 FIRST-IN-HUMAN

  • NCT06735209 (posted Aug 7, 2026): a randomized, double-blind, placebo-controlled Phase 1 trial enrolling up to 22 malaria-naive adults to test the genetically attenuated Plasmodium falciparum sporozoite vaccine PfSPZ-LARC2 for safety, immunogenicity, and efficacy.

📢 PUBLIC HEALTH

U.S. COMPLETES WHO WITHDRAWAL

  • The United States formally completed its withdrawal from the World Health Organization, effective January 22, 2026, citing COVID-19 failures and politicization; WHO stated the withdrawal "makes both the United States and the world less safe."
  • The U.S. exit reduces WHO's funding base at a time of active Ebola, hantavirus, Nipah, and yellow fever emergencies.

TIMOR-LESTE CERTIFIED MALARIA-FREE BY WHO

  • WHO certified Timor-Leste as malaria-free on July 23, 2025, following a national elimination campaign launched shortly after independence in 2002 — a landmark public health achievement.

WEST NILE VIRUS — EARLY RECORD SEASON, U.S.

  • CDC warned on July 1, 2026, of an early West Nile virus season with record case numbers, urging Americans to use mosquito repellent during America's 250th Independence Day holiday weekend and beyond.

TICK BITE ER VISITS — ABOVE NORMAL

  • CDC data (April 23, 2026) show weekly emergency department visits for tick bites are higher than usual, with Lyme disease and other tickborne illnesses expanding geographically.

CDC NEW DIRECTOR SWORN IN

  • Susan Monarez, Ph.D., was sworn in as CDC Director on July 31, 2025, under HHS Secretary Robert F. Kennedy Jr., as part of the "Make America Healthy Again" agenda.

FREE MIND CAMPAIGN — YOUTH SUBSTANCE USE AND MENTAL HEALTH

  • CDC launched its "Free Mind" campaign on August 5, 2026, providing teens with resources addressing substance use and mental health, as national data continue to show improvements in some youth mental health indicators.

This briefing is informational only and does not constitute medical advice. Always consult qualified healthcare providers for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  5. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  6. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  7. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  8. Transcript - Update on CDC's Hantavirus Response - 6/24/26 — CDC Newsroom
  9. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News
  10. Shredded iceberg lettuce served at Taco Bell locations is sour… — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260810-02-v51 · 2026-08-10 02:02 UTC · pulse.uzylab.com

Read next